Asen Bagashev
Vice President, In Vivo Cell Therapies Velvet Therapeutics
Seminars
Thursday 30th July 2026
Exploring a Differentiated DNA Based Delivery Platform Bridging LNP & Lentiviral Modalities for Safer In Vivo CAR Applications
10:00 am
- Comparing DNA‑based nanoparticle delivery with LNP and lentiviral systems, enabling stronger, longer yet non‑integrating gene expression to enhance therapeutic optionality
- Revealing emerging biodistribution insights including an unexpected liver‑escape profile, expanding understanding of tissue targeting and informing future mechanism‑of‑action work
- Highlighting manufacturing simplicity, safety signals, and unpublished preclinical data, equipping attendees with actionable perspectives on platform readiness and translational potential
